Kronos Bio (KRON) News Today $0.69 +0.02 (+3.13%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KRON Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRONMay 4, 2025 | businesswire.comConcentra To Acquire Kronos BioMay 3, 2025 | nasdaq.comKronos Bio (KRON) Projected to Announce Quarterly Earnings on ThursdayKronos Bio (NASDAQ:KRON) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-kronos-bio-inc-stock/)May 3, 2025 | marketbeat.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRONMay 1, 2025 | prnewswire.comKronos Bio Agrees to Be Acquired by Concentra BiosciencesMay 1, 2025 | marketwatch.comShareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public ShareholdersMay 1, 2025 | businesswire.comKRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to ShareholdersMay 1, 2025 | businesswire.comKronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value RightMay 1, 2025 | finance.yahoo.comKronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value RightMay 1, 2025 | globenewswire.comKronos Bio, Inc. (NASDAQ:KRON) Sees Significant Decrease in Short InterestKronos Bio, Inc. (NASDAQ:KRON - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 611,600 shares, a drop of 18.2% from the March 15th total of 748,000 shares. Based on an average trading volume of 188,000 shares, the short-interest ratio is currently 3.3 days. Approximately 1.6% of the shares of the stock are sold short.April 22, 2025 | marketbeat.comShort Interest in Kronos Bio, Inc. (NASDAQ:KRON) Drops By 13.4%Kronos Bio, Inc. (NASDAQ:KRON - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 748,000 shares, a drop of 13.4% from the February 28th total of 863,500 shares. Based on an average daily volume of 231,500 shares, the days-to-cover ratio is currently 3.2 days. Approximately 1.9% of the shares of the company are sold short.April 4, 2025 | marketbeat.comKronos Bio Reports 2024 Financial ResultsMarch 27, 2025 | tipranks.comKronos Bio Full Year 2024 Earnings: US$1.43 loss per share (vs US$1.95 loss in FY 2023)March 20, 2025 | finance.yahoo.comKronos Bio reports Q4 EPS (43c) vs. (43c ) last yearMarch 19, 2025 | markets.businessinsider.comKronos Bio (NASDAQ:KRON) Issues Earnings ResultsKronos Bio (NASDAQ:KRON - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.13). Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%.March 19, 2025 | marketbeat.comKronos Bio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 18, 2025 | globenewswire.comKronos Bio (KRON) to Release Quarterly Earnings on ThursdayKronos Bio (NASDAQ:KRON) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comKronos Bio (NASDAQ:KRON) Stock Price Down 1% - Should You Sell?Kronos Bio (NASDAQ:KRON) Stock Price Down 1% - What's Next?March 12, 2025 | marketbeat.comKronos Bio Insider Ups Holding By 36% During YearFebruary 23, 2025 | uk.finance.yahoo.comPartners Capital Investment Group LLP Sells 1,084,012 Shares of Kronos Bio, Inc. (NASDAQ:KRON)Partners Capital Investment Group LLP lessened its position in Kronos Bio, Inc. (NASDAQ:KRON - Free Report) by 67.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 527,500 shares of the company's stock afteFebruary 17, 2025 | marketbeat.comPeapod Lane Capital LLC Acquires Shares of 562,620 Kronos Bio, Inc. (NASDAQ:KRON)Peapod Lane Capital LLC bought a new stake in Kronos Bio, Inc. (NASDAQ:KRON - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 562,620 shares of the company's stock, valued at approximately $534,00February 13, 2025 | marketbeat.comKronos Bio, Inc. (NASDAQ:KRON) Short Interest Up 16.5% in DecemberKronos Bio, Inc. (NASDAQ:KRON - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 577,700 shares, a growth of 16.5% from the December 15th total of 496,000 shares. Approximately 1.5% of the company's stock are sold short. Based on an average trading volume of 255,900 shares, the short-interest ratio is presently 2.3 days.January 19, 2025 | marketbeat.comWe Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth CarefullyJanuary 13, 2025 | uk.finance.yahoo.comKronos Bio (NASDAQ:KRON) Stock Price Down 1.8% - Here's What HappenedKronos Bio (NASDAQ:KRON) Trading Down 1.8% - What's Next?January 1, 2025 | marketbeat.comKronos Bio Ends Collaboration with Genentech and RocheDecember 27, 2024 | tipranks.comKronos Bio Inc Ordinary SharesDecember 13, 2024 | morningstar.comKronos Bio (NASDAQ:KRON) Shares Up 8.5% - Still a Buy?Kronos Bio (NASDAQ:KRON) Stock Price Up 8.5% - Still a Buy?December 6, 2024 | marketbeat.comStruggling Bay Area biotech firm Kronos, once worth $1B, lays off almost entire staffDecember 4, 2024 | msn.comKronos Bio announces workforce reduction of 83% by year-endNovember 28, 2024 | markets.businessinsider.comKronos Bio to lay off 83% of staff as CEO steps downNovember 28, 2024 | bizjournals.comBiotech with Cambridge lab slashes 83% of staff, CEO departsNovember 28, 2024 | bizjournals.comKronos Bio CEO Norbert Bischofberger steps down, Deborah Knobelman named interimNovember 28, 2024 | markets.businessinsider.comKronos Bio announces interim CEO; over 80% of staff reductionNovember 28, 2024 | msn.comKronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-UpNovember 28, 2024 | msn.comKronos Bio Announces CEO Transition and Reduction in ForceNovember 27, 2024 | globenewswire.comPetri Dish: Kronos Bio seeks merger; Former Biogen R&D head joins investment firmNovember 22, 2024 | bizjournals.comKronos Bio Third Quarter 2024 Earnings: Beats ExpectationsNovember 16, 2024 | finance.yahoo.comKronos Bio to present preclinical data from p300 KAT inhibitor programNovember 16, 2024 | markets.businessinsider.comKronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic AlternativesNovember 15, 2024 | uk.finance.yahoo.comKronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024November 14, 2024 | globenewswire.comTD Cowen downgrades Kronos Bio (KRON) to a HoldNovember 14, 2024 | markets.businessinsider.comKronos Bio downgraded to Hold from Buy at TD CowenNovember 14, 2024 | markets.businessinsider.comKronos mulls ‘strategic alternatives’ after axing cancer drug developmentNovember 14, 2024 | yahoo.comKronos Bio (NASDAQ:KRON) Rating Lowered to "Neutral" at Piper SandlerPiper Sandler lowered shares of Kronos Bio from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $6.00 to $1.00 in a report on Thursday.November 14, 2024 | marketbeat.comKronos Bio (NASDAQ:KRON) Stock Rating Lowered by TD CowenTD Cowen downgraded Kronos Bio from a "buy" rating to a "hold" rating in a report on Thursday.November 14, 2024 | marketbeat.comKronos Bio files $250M mixed securities shelfNovember 8, 2024 | markets.businessinsider.comKronos Bio to present data at ASH annual meeting on p300 KAT inhibitor programNovember 5, 2024 | markets.businessinsider.comKronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple MyelomaNovember 5, 2024 | finance.yahoo.comKronos Bio announces preclinical data from p300 KAT inhibitor programOctober 24, 2024 | markets.businessinsider.comKronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven TumorsOctober 23, 2024 | globenewswire.com Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address KRON Media Mentions By Week KRON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KRON News Sentiment▼0.000.65▲Average Medical News Sentiment KRON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KRON Articles This Week▼01▲KRON Articles Average Week Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SLS News Today CYBN News Today ACOG News Today FDMT News Today MOLN News Today RNAZ News Today DERM News Today KRRO News Today ACRS News Today FATE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KRON) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
